Qiagen N.V. (QGEN)

$41.45 +0.88 (2.17%)
Market Cap 8.36B
Revenue (ttm) 2.09B
Net Income (ttm) 424.88M
EPS (ttm) N/A
PE Ratio 16.65
Forward PE 16.70
Profit Margin 20.33%
Debt to Equity Ratio 0.49
Volume 2,725,500
Avg Vol 2,710,606
Day's Range N/A - N/A
Shares Out 206.08M
Stochastic %K 74%
Beta 0.64
Analysts Sell
Price Target $42.43

Company Profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nuc...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 31 77 355 6600
Address:
Hulsterweg 82, Venlo, Netherlands
Src947
Src947 Jul. 23 at 9:31 PM
$QGEN think buyout 50-51. Could be 48-50.
1 · Reply
StockConsultant
StockConsultant Jul. 17 at 4:13 AM
$QGEN Qiagen stock, watch for a bull flag breakout at https://stockconsultant.com/?QGEN Breakout trade WATCH for possible breakout above 42.42 Target: 46.2, 11.3% Stop: 40.41 Loss: 2.6% P/L ratio: 4.3 : 1 - Excellent BULLISH [Timing] Mild bullish 3 day candlestick pattern with Strong 3 day accumulation. [Timing] breakout watch above 42.42, no resistance in area just above. BEARISH [Positioning] Overbought, odds favor short trades. [Positioning] Intermediate trend possibly bearish, Sideways trend near upper resistance. [Positioning] at resistance
0 · Reply
Anitya123
Anitya123 Jul. 15 at 1:44 PM
$QGEN wen news ?
0 · Reply
Theflash88
Theflash88 Jul. 14 at 5:36 PM
$QGEN $60 a share.
0 · Reply
Riteman
Riteman Jul. 13 at 4:41 PM
$QGEN easiest buy. Offers outstanding for $50/share. No buy, settles down to $38/share, buy 20% profit
0 · Reply
JustB4SnR1se
JustB4SnR1se Jul. 10 at 12:35 PM
$QGEN 👀
0 · Reply
mikesterz7
mikesterz7 Jul. 9 at 7:50 PM
$QGEN $KRRO Some potential bidders are considering an offer of at least $50 per share
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 9 at 5:19 PM
QGEN Stock Clocks Biggest Single-Day Gains In Nearly Six Months – Investor Optimism Jumps On Report About Takeover Interest $QGEN $KKR https://stocktwits.com/news/equity/markets/qgen-stock-gains-on-takeover-report/cZmY5exR7nV
0 · Reply
prismmarketview
prismmarketview Jul. 9 at 4:44 PM
$QGEN back in play. Reports say Qiagen is exploring “strategic options” (read: potential sale) after fresh interest from buyout firms and strategics. Big move up already, but still no official bid on the table. #QGEN #MNA #Biotech https://prismmarketview.com/qiagen-shares-climb-on-fresh-takeover-talk/
0 · Reply
notreload_ai
notreload_ai Jul. 9 at 3:55 PM
$QGEN is attracting preliminary takeover interest from private equity giants EQT, Advent International, and KKR. No formal bids yet as the ~$9B molecular diagnostics leader faces sector consolidation. https://notreload.xyz/xy/qiagen-draws-early-takeover-interest-from-eqt-advent-kkr/
0 · Reply
Latest News on QGEN
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Jul 15, 2026, 4:05 PM EDT - 8 days ago

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Jul 15, 2026, 8:48 AM EDT - 8 days ago

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Qiagen price target raised to $44 from $40 at TD Cowen

2026-07-15T12:45:38.000Z - 8 days ago

Qiagen price target raised to $44 from $40 at TD Cowen

Qiagen expands QIAstat-Dx bloodstream infection testing menu in Europe

2026-07-14T20:10:53.000Z - 9 days ago

Qiagen expands QIAstat-Dx bloodstream infection testing menu in Europe

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Jul 14, 2026, 4:05 PM EDT - 9 days ago

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Qiagen downgraded to Hold from Buy at Berenberg

2026-07-14T08:40:23.000Z - 10 days ago

Qiagen downgraded to Hold from Buy at Berenberg

Qiagen gains after report of early PE interest including EQT, Advent

2026-07-09T15:10:12.000Z - 14 days ago

Qiagen gains after report of early PE interest including EQT, Advent

KKR

Qiagen draws early takeover interest from EQT, Advent & KKR, Bloomberg News reports

Jul 9, 2026, 11:04 AM EDT - 14 days ago

Qiagen draws early takeover interest from EQT, Advent & KKR, Bloomberg News reports

KKR

Qiagen drawing takeover interest from Advent, EQT, Bloomberg reports

2026-07-09T14:40:38.000Z - 14 days ago

Qiagen drawing takeover interest from Advent, EQT, Bloomberg reports

Qiagen initiated with a Hold at Kepler Cheuvreux

2026-06-25T08:40:08.000Z - 4 weeks ago

Qiagen initiated with a Hold at Kepler Cheuvreux

Qiagen Transcript: AGM 2026

Jun 24, 2026, 3:00 AM EDT - 4 weeks ago

Qiagen Transcript: AGM 2026

Qiagen Slides: FY 2026

Jun 24, 2026, 3:00 AM EDT - 4 weeks ago

Qiagen Slides: FY 2026

Qiagen upgraded to Overweight from Equal Weight at Morgan Stanley

2026-06-23T08:25:49.000Z - 4 weeks ago

Qiagen upgraded to Overweight from Equal Weight at Morgan Stanley

Qiagen Transcript: Investor update

Jun 15, 2026, 10:00 AM EDT - 5 weeks ago

Qiagen Transcript: Investor update

Qiagen Slides: Investor update

Jun 15, 2026, 10:00 AM EDT - 5 weeks ago

Qiagen Slides: Investor update

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Jun 15, 2026, 1:30 AM EDT - 5 weeks ago

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Qiagen Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:40 AM EDT - 7 weeks ago

Qiagen Transcript: Jefferies Global Healthcare Conference 2026

Qiagen Slides: FY 2026

Jun 3, 2026, 11:40 AM EDT - 7 weeks ago

Qiagen Slides: FY 2026

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

May 28, 2026, 4:05 PM EDT - 2 months ago

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

May 20, 2026, 4:05 PM EDT - 2 months ago

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Qiagen Digital Insights to integrate Nvidia accelerated computing

2026-05-19T20:17:32.000Z - 2 months ago

Qiagen Digital Insights to integrate Nvidia accelerated computing

NVDA

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

May 19, 2026, 4:05 PM EDT - 2 months ago

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

Qiagen price target lowered to $36 from $50 at Stifel

2026-05-18T10:47:09.000Z - 2 months ago

Qiagen price target lowered to $36 from $50 at Stifel

Qiagen Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 6:00 PM EDT - 2 months ago

Qiagen Transcript: Bank of America Global Healthcare Conference 2026

Qiagen Slides: FY 2026

May 12, 2026, 6:00 PM EDT - 2 months ago

Qiagen Slides: FY 2026

QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

May 12, 2026, 2:00 AM EDT - 2 months ago

QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

Qiagen price target lowered to $40 from $46 at TD Cowen

2026-05-07T20:13:08.000Z - 2 months ago

Qiagen price target lowered to $40 from $46 at TD Cowen

Qiagen Transcript: Status update

May 7, 2026, 9:30 AM EDT - 2 months ago

Qiagen Transcript: Status update

Qiagen Slides: Status update

May 7, 2026, 9:30 AM EDT - 2 months ago

Qiagen Slides: Status update

Qiagen Slides: Investor presentation

May 7, 2026, 7:00 AM EDT - 2 months ago

Qiagen Slides: Investor presentation

QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing

May 7, 2026, 6:00 AM EDT - 2 months ago

QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing

Qiagen reports Q1 EPS 54c, consensus 54c

2026-05-07T00:35:14.000Z - 2 months ago

Qiagen reports Q1 EPS 54c, consensus 54c

QIAGEN Reports Full Results for Q1 2026

May 6, 2026, 4:05 PM EDT - 2 months ago

QIAGEN Reports Full Results for Q1 2026

Qiagen Earnings release: Q1 2026

May 6, 2026, 7:00 AM EDT - 2 months ago

Qiagen Earnings release: Q1 2026

Qiagen price target lowered to $43 from $54 at Deutsche Bank

2026-04-30T14:23:05.000Z - 3 months ago

Qiagen price target lowered to $43 from $54 at Deutsche Bank

Qiagen price target lowered to EUR 34 from EUR 44 at Morgan Stanley

2026-04-29T15:46:51.000Z - 3 months ago

Qiagen price target lowered to EUR 34 from EUR 44 at Morgan Stanley

Qiagen price target lowered to $45 from $60 at JPMorgan

2026-04-29T14:06:09.000Z - 3 months ago

Qiagen price target lowered to $45 from $60 at JPMorgan

Qiagen price target lowered to $38 from $55 at Citi

2026-04-29T10:54:24.000Z - 3 months ago

Qiagen price target lowered to $38 from $55 at Citi

Qiagen price target lowered to $38 from $44 at Barclays

2026-04-29T09:42:38.000Z - 3 months ago

Qiagen price target lowered to $38 from $44 at Barclays

Qiagen upgraded to Outperform from Neutral at Baird

2026-04-29T09:05:34.000Z - 3 months ago

Qiagen upgraded to Outperform from Neutral at Baird

Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Apr 28, 2026, 8:30 PM EDT - 3 months ago

Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Qiagen Transcript: Investor update

Apr 28, 2026, 9:30 AM EDT - 3 months ago

Qiagen Transcript: Investor update

Qiagen Slides: Investor update

Apr 28, 2026, 9:30 AM EDT - 3 months ago

Qiagen Slides: Investor update

Qiagen Earnings release: Investor update

Apr 28, 2026, 9:30 AM EDT - 3 months ago

Qiagen Earnings release: Investor update

QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook

Apr 27, 2026, 4:16 PM EDT - 3 months ago

QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook

QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026

Apr 16, 2026, 4:05 PM EDT - 3 months ago

QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026

QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel

Apr 14, 2026, 4:05 PM EDT - 3 months ago

QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel

Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis

Mar 31, 2026, 12:40 PM EDT - 4 months ago

Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis

Qiagen Announces Form 20-F Annual Report Filing for 2025 Results

Mar 20, 2026, 7:30 AM EDT - 4 months ago

Qiagen Announces Form 20-F Annual Report Filing for 2025 Results

QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

Mar 19, 2026, 4:05 PM EDT - 4 months ago

QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System

Mar 10, 2026, 5:05 PM EDT - 4 months ago

QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System

Qiagen Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:30 AM EDT - 4 months ago

Qiagen Transcript: Barclays 28th Annual Global Healthcare Conference

Qiagen Slides: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:30 AM EDT - 4 months ago

Qiagen Slides: Barclays 28th Annual Global Healthcare Conference

Qiagen Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 11:20 AM EDT - 4 months ago

Qiagen Transcript: Leerink Global Healthcare Conference 2026

Qiagen Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 5 months ago

Qiagen Transcript: TD Cowen 46th Annual Health Care Conference

Qiagen Slides: Investor presentation

Feb 24, 2026, 7:00 AM EST - 5 months ago

Qiagen Slides: Investor presentation

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

Feb 19, 2026, 8:00 AM EST - 5 months ago

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

Qiagen Earnings Call Transcript: Q4 2025

Feb 5, 2026, 9:30 AM EST - 6 months ago

Qiagen Earnings Call Transcript: Q4 2025

Qiagen Annual report: Q4 2025

Feb 5, 2026, 9:30 AM EST - 6 months ago

Qiagen Annual report: Q4 2025

Qiagen Earnings release: Q4 2025

Feb 5, 2026, 9:30 AM EST - 6 months ago

Qiagen Earnings release: Q4 2025

Qiagen Slides: Q4 2025

Feb 5, 2026, 9:30 AM EST - 6 months ago

Qiagen Slides: Q4 2025

Qiagen Annual report: Q4 2025

Feb 5, 2026, 9:30 AM EST - 6 months ago

Qiagen Annual report: Q4 2025

QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

Feb 4, 2026, 4:05 PM EST - 6 months ago

QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

Feb 3, 2026, 4:05 PM EST - 6 months ago

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

QIAGEN Appoints Mark Stevenson to Supervisory Board

Jan 26, 2026, 4:05 PM EST - 6 months ago

QIAGEN Appoints Mark Stevenson to Supervisory Board

Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports

Jan 20, 2026, 12:19 PM EST - 6 months ago

Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports

QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

Jan 19, 2026, 9:56 AM EST - 6 months ago

QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

Qiagen Slides: Investor presentation

Jan 16, 2026, 7:00 AM EST - 6 months ago

Qiagen Slides: Investor presentation

Qiagen Slides: Investor presentation

Jan 13, 2026, 7:00 AM EST - 6 months ago

Qiagen Slides: Investor presentation

QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

Jan 12, 2026, 2:00 AM EST - 6 months ago

QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

Qiagen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 7:00 PM EST - 6 months ago

Qiagen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Qiagen Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 7:00 PM EST - 6 months ago

Qiagen Slides: 44th Annual J.P. Morgan Healthcare Conference

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

Dec 18, 2025, 11:27 AM EST - 7 months ago

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

Qiagen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:50 AM EST - 8 months ago

Qiagen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Qiagen Slides: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:50 AM EST - 8 months ago

Qiagen Slides: Evercore ISI 8th Annual HealthCONx Conference

Qiagen Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 11:15 AM EST - 8 months ago

Qiagen Transcript: Citi Annual Global Healthcare Conference 2025

Qiagen Transcript: Status Update

Nov 21, 2025, 9:00 AM EST - 8 months ago

Qiagen Transcript: Status Update

Qiagen Slides: Status Update

Nov 21, 2025, 9:00 AM EST - 8 months ago

Qiagen Slides: Status Update

Qiagen Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 5:30 AM EST - 8 months ago

Qiagen Transcript: Jefferies London Healthcare Conference 2025

Qiagen Transcript: Wolfe Research Healthcare Conference 2025

Nov 17, 2025, 12:40 PM EST - 8 months ago

Qiagen Transcript: Wolfe Research Healthcare Conference 2025

Qiagen Slides: FY 2025

Nov 17, 2025, 12:40 PM EST - 8 months ago

Qiagen Slides: FY 2025

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

Nov 10, 2025, 1:30 AM EST - 9 months ago

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

Seattle's Parse Biosciences to be acquired by Qiagen for $225M

Nov 6, 2025, 1:49 PM EST - 9 months ago

Seattle's Parse Biosciences to be acquired by Qiagen for $225M

Qiagen Earnings Call Transcript: Q3 2025

Nov 5, 2025, 9:30 AM EST - 9 months ago

Qiagen Earnings Call Transcript: Q3 2025

Qiagen Earnings release: Q3 2025

Nov 5, 2025, 9:30 AM EST - 9 months ago

Qiagen Earnings release: Q3 2025

Qiagen Slides: Q3 2025

Nov 5, 2025, 9:30 AM EST - 9 months ago

Qiagen Slides: Q3 2025

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

Nov 4, 2025, 1:04 PM EST - 9 months ago

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

Nov 4, 2025, 1:03 PM EST - 9 months ago

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

Oct 28, 2025, 5:05 PM EDT - 9 months ago

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

Oct 13, 2025, 8:24 AM EDT - 10 months ago

QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

Qiagen Transcript: Bank of America Global Healthcare Conference 2025

Sep 25, 2025, 5:45 AM EDT - 10 months ago

Qiagen Transcript: Bank of America Global Healthcare Conference 2025

Qiagen Slides: FY 2025

Sep 25, 2025, 5:45 AM EDT - 10 months ago

Qiagen Slides: FY 2025

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

Sep 10, 2025, 4:05 PM EDT - 11 months ago

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

Qiagen Transcript: Baird Global Healthcare Conference 2025

Sep 10, 2025, 1:25 PM EDT - 11 months ago

Qiagen Transcript: Baird Global Healthcare Conference 2025

Qiagen Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 1:05 PM EDT - 11 months ago

Qiagen Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

Sep 2, 2025, 1:30 AM EDT - 11 months ago

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

Aug 28, 2025, 5:08 PM EDT - 11 months ago

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

Src947
Src947 Jul. 23 at 9:31 PM
$QGEN think buyout 50-51. Could be 48-50.
1 · Reply
StockConsultant
StockConsultant Jul. 17 at 4:13 AM
$QGEN Qiagen stock, watch for a bull flag breakout at https://stockconsultant.com/?QGEN Breakout trade WATCH for possible breakout above 42.42 Target: 46.2, 11.3% Stop: 40.41 Loss: 2.6% P/L ratio: 4.3 : 1 - Excellent BULLISH [Timing] Mild bullish 3 day candlestick pattern with Strong 3 day accumulation. [Timing] breakout watch above 42.42, no resistance in area just above. BEARISH [Positioning] Overbought, odds favor short trades. [Positioning] Intermediate trend possibly bearish, Sideways trend near upper resistance. [Positioning] at resistance
0 · Reply
Anitya123
Anitya123 Jul. 15 at 1:44 PM
$QGEN wen news ?
0 · Reply
Theflash88
Theflash88 Jul. 14 at 5:36 PM
$QGEN $60 a share.
0 · Reply
Riteman
Riteman Jul. 13 at 4:41 PM
$QGEN easiest buy. Offers outstanding for $50/share. No buy, settles down to $38/share, buy 20% profit
0 · Reply
JustB4SnR1se
JustB4SnR1se Jul. 10 at 12:35 PM
$QGEN 👀
0 · Reply
mikesterz7
mikesterz7 Jul. 9 at 7:50 PM
$QGEN $KRRO Some potential bidders are considering an offer of at least $50 per share
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 9 at 5:19 PM
QGEN Stock Clocks Biggest Single-Day Gains In Nearly Six Months – Investor Optimism Jumps On Report About Takeover Interest $QGEN $KKR https://stocktwits.com/news/equity/markets/qgen-stock-gains-on-takeover-report/cZmY5exR7nV
0 · Reply
prismmarketview
prismmarketview Jul. 9 at 4:44 PM
$QGEN back in play. Reports say Qiagen is exploring “strategic options” (read: potential sale) after fresh interest from buyout firms and strategics. Big move up already, but still no official bid on the table. #QGEN #MNA #Biotech https://prismmarketview.com/qiagen-shares-climb-on-fresh-takeover-talk/
0 · Reply
notreload_ai
notreload_ai Jul. 9 at 3:55 PM
$QGEN is attracting preliminary takeover interest from private equity giants EQT, Advent International, and KKR. No formal bids yet as the ~$9B molecular diagnostics leader faces sector consolidation. https://notreload.xyz/xy/qiagen-draws-early-takeover-interest-from-eqt-advent-kkr/
0 · Reply
JustB4SnR1se
JustB4SnR1se Jul. 9 at 2:33 PM
$QGEN
0 · Reply
Anitya123
Anitya123 Jul. 9 at 2:25 PM
$QGEN https://www.bloomberg.com/news/articles/2026-07-09/qiagen-draws-early-takeover-interest-from-eqt-advent
0 · Reply
MaverikIT
MaverikIT Jul. 9 at 2:23 PM
$QGEN @Jblack500 @No_Face_character @WAJeff @BustaCapital @cynicaloptimist @IsabellaDC
0 · Reply
Riteman
Riteman Jul. 9 at 2:23 PM
$QGEN Shareholders rejected a $42 sp, $11B valuation. A decent target would be $13B at $60 sp.
0 · Reply
Theflash88
Theflash88 Jul. 9 at 2:20 PM
$QGEN Told you so!
1 · Reply
Anitya123
Anitya123 Jul. 9 at 2:18 PM
$QGEN any news ?
0 · Reply
AlertsAndNews
AlertsAndNews Jul. 9 at 2:17 PM
$QGEN quite the options flows surge here.
1 · Reply
JustB4SnR1se
JustB4SnR1se Jul. 9 at 2:15 PM
$QGEN 🗽
0 · Reply
Theflash88
Theflash88 Jun. 24 at 7:15 PM
$QGEN Ok… something is cooking! Up almost every day for awhile now no matter what the market is doing. I smell a buyout.
1 · Reply
StockpeakHQ_1
StockpeakHQ_1 Jun. 24 at 1:40 PM
Opened 100 $QGEN 40C 08/21 @ $2.00 ( actual Cost: $2.00)
0 · Reply
JustB4SnR1se
JustB4SnR1se Jun. 24 at 1:40 PM
$QGEN 👀
0 · Reply
QuantInsider
QuantInsider Jun. 24 at 1:01 AM
$QGEN popping today with a 2.5% rally Morgan Stanley's upgrade to Overweight and a $42 target is driving this Big Aug $40 call sweeps hitting, 5,861 contracts bought at 7 to 8% OTM That's a hefty $947K in premium, way above the usual action Almost the whole week's move happened today If this isn't a one-day wonder, we might see more upside Keep an eye on whether this bullish positioning holds up
0 · Reply